Icon

Reference Library

This reference library includes key clinical papers, links to useful resources and national guidance to inform your practice.

Clinical Studies  Clinical Studies
Resources  Resources
Guidelines  Guidelines

Clinical Studies

icon

Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people

Khunti K, Wolden ML, Thorsted BL, et al
Diabetes Care 2013;36(11):3411–7

icon

Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes

Paul SK, et al
Cardiovascular Diabetol 2015;14:100-10

icon

Effects of intensive glucose lowering in type 2 diabetes

ACCORD Study Group
N Engl J Med 2008;358:2545–59

icon

Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes

Zaccardi F, et al
Diabetes Obes Metab 2016;18(8):738-94

icon

Factors associated with clinical inertia: an integrative review

Aujoulat I, Jacquemin P, Rietzscel E, et al
Adv Med Educ Pract 2014;5:141–7

icon

Sustained effect of intensive treatment of diabetes mellitus on development and progression of diabetic nephropathy

Epidemiology of Diabetes Interventions and Complications Study (EDIC) Group.
JAMA 2003;290(16):2159–67

icon

The kidney as a treatment target for type 2 diabetes

Dokken E
Diabetes Spectrum 2012;25(1):29-36

icon

UKPDS and the Legacy Effect

Chalmers J et al
N Engl J Med 2008;359:1618–20

icon

10-year follow-up of intensive glucose control in type 2 diabetes

Holman RR, Paul SK, Bethel MA, et al
N Engl J Med 2008;359:1577–1589

icon

Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: Identification of risk and management in type 2 diabetes

Seidu S, Barrat J, Khunti K
Primary Care Diabates 2020;14(4):370-375

icon

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

Wilding J, Fernando K, Milne K et al
Diabetes Therapy 2018; 9:1757-1773

icon

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Ali A, Bain S, Hicks D et al
Diabates Therapy 2019; 10:1595-1622

Resources

icon

Assessing fitness to drive: a guide for medical professionals

DVLA

icon

Facts and Stats, 2016

Diabetes UK

icon

National Diabetes Audit 2016-17

NHS Digital

icon

New diagnostic criteria for diabetes (Jan 2011) – Use of haemoglobin A1c (HbA1c) in the diagnosis of diabetes mellitus in the UK

Diabetes UK

icon

Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus

WHO

Guidelines and clinical standards

icon

American Diabetes Association. Standards of Medical Care in Diabetes–2019. Abridged for primary care providers. American Diabetes Association.

ADA
Clinical Diabetes 2019 Jan; 37(1):11-34

icon

NG136. Hypertension in adults (2019). Diagnosis and management

NICE

icon

CG182. Chronic kidney disease in adults: assessment and management (2014)

NICE

icon

Diabetes in adults (QS6)

NICE

icon

KDIGO Diabetes and CKD, Scope of work, 2018.

KIDGO

icon

Management of Hyperglycemia in Type 2 Diabetes, 2018

ADA/EASD

icon

NICE Pathways. Type 2 diabetes in adults, 2019

NICE

icon

Pharmacological management of glycaemic control in people with Type 2 Diabetes

SIGN 154

icon

2019/20 General Medical Services (GMS) contract: Quality and Outcomes Framework (QOF), April 2019

BMA/NHS England

icon

American Diabetes Association and the European Association for the Study of Diabetes, Consensus report, 2019

ADA/EASD

PATIENT RESOURCES